|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
(Suppl 5):v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stinchcombe TE, Lee CB and Socinski MA:
Current approaches to advanced-stage non-small-cell lung cancer:
First-line therapy in patients with a good functional status. Clin
Lung Cancer. 7 (Suppl 4):S111–S117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brodowicz T, O'Byrne K and Manegold C:
Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coello MC, Luketich JD, Litle VR and
Godfrey TE: Prognostic significance of micrometastasis in
non-small-cell lung cancer. Clin Lung Cancer. 5:214–225. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsuya A and Fukuoka M: Bone metastases in
lung cancer. Clin Calcium. 18:455–459. 2008.(In Japanese).
PubMed/NCBI
|
|
8
|
Dhillon S: Zoledronic Acid (Reclast((R)),
Aclasta((R))): A Review in Osteoporosis. Drugs. 76:1683–1697. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dunford JE, Thompson K, Coxon FP, Luckman
SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ:
Structure-activity relationships for inhibition of farnesyl
diphosphate synthase in vitro and inhibition of bone resorption in
vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther.
296:235–242. 2001.PubMed/NCBI
|
|
10
|
Li YY, Chang JW, Chou WC, Liaw CC, Wang
HM, Huang JS, Wang CH and Yeh KY: Zoledronic acid is unable to
induce apoptosis, but slows tumor growth and prolongs survival for
non-small-cell lung cancers. Lung Cancer. 59:180–191. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu S, Zhang J, Zhou Z, Liao ML, He WZ,
Zhou XY, Li ZM, Xiang JQ, Wang JJ and Chen HQ: Synergistic
inhibitory activity of zoledronate and paclitaxel on bone
metastasis in nude mice. Oncol Rep. 20:581–587. 2008.PubMed/NCBI
|
|
12
|
Huang CY, Wang L, Feng CJ, Yu P, Cai XH,
Yao WX, Xu Y, Liu XK, Zhu WJ, Wang Y, et al: Bisphosphonates
enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR
activating mutation: A retrospective study. Oncotarget.
7:66480–66490. 2016.PubMed/NCBI
|
|
13
|
Zhang G, Cheng R, Zhang Z, Jiang T, Ren S,
Ma Z, Zhao S, Zhou C and Zhang J: Bisphosphonates enhance antitumor
effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and
bone metastases. Sci Rep. 7:429792017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lein M, Wirth M, Miller K, Eickenberg HU,
Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA
and Jung K: Serial markers of bone turnover in men with metastatic
prostate cancer treated with zoledronic Acid for detection of bone
metastases progression. Eur Urol. 52:1381–1387. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chia PL, Mitchell P, Dobrovic A and John
T: Prevalence and natural history of ALK positive non-small-cell
lung cancer and the clinical impact of targeted therapy with ALK
inhibitors. Clin Epidemiol. 6:423–432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
19
|
ESMO Guidelines Committee, . Appendix 8:
Metastatic non-small-cell lung cancer (2): eUpdate published online
28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). Ann
Oncol. 28 (Suppl_4):iv162–iv164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pilkington G, Boland A, Brown T, Oyee J,
Bagust A and Dickson R: A systematic review of the clinical
effectiveness of first-line chemotherapy for adult patients with
locally advanced or metastatic non-small cell lung cancer. Thorax.
70:359–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang JW, Hsieh JJ, Shen YC, Yeh KY, Wang
CH, Li YY and Hsu T: Bisphosphonate zoledronic acid enhances the
inhibitory effects of gefitinib on EGFR-mutated non-small cell lung
carcinoma cells. Cancer Lett. 278:17–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melisi D, Caputo R, Damiano V, Bianco R,
Veneziani BM, Bianco AR, De Placido S, Ciardiello F and Tortora G:
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and
gefitinib in inhibiting breast and prostate cancer. Endocr Relat
Cancer. 12:1051–1058. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stachnik A, Yuen T, Iqbal J, Sgobba M,
Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, et al:
Repurposing of bisphosphonates for the prevention and therapy of
nonsmall cell lung and breast cancer. Proc Natl Acad Sci USA.
111:17995–18000. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cook RJ, Coleman R, Brown J, Lipton A,
Major P, Hei YJ, Saad F and Smith MR: Markers of bone metabolism
and survival in men with hormone-refractory metastatic prostate
cancer. Clin Cancer Res. 12:3361–3367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aruga A, Koizumi M, Hotta R, Takahashi S
and Ogata E: Usefulness of bone metabolic markers in the diagnosis
and follow-up of bone metastasis from lung cancer. Br J Cancer.
76:760–764. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Du WX, Duan SF, Chen JJ, Huang JF, Yin LM
and Tong PJ: Serum bone-specific alkaline phosphatase as a
biomarker for osseous metastases in patients with malignant
carcinomas: A systematic review and meta-analysis. J Cancer Res
Ther. 10 (Suppl):C140–C143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Yi M, Cao J, Hou C, Zhou Y and
Zhong Y: Serum cross-linked N-telopeptide of type I collagen for
the diagnosis of bone metastases from solid tumours in the Chinese
population: Meta-analysis. J Int Med Res. 44:192–200. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Oronzo S, Brown J and Coleman R: The
role of biomarkers in the management of bone-homing malignancies. J
Bone Oncol. 9:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coleman RE, Lipton A, Costa L, Cook RJ,
Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, et al:
Possible survival benefits from zoledronic acid treatment in
patients with bone metastases from solid tumours and poor
prognostic features-An exploratory analysis of placebo-controlled
trials. J Bone Oncol. 2:70–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferreira A, Alho I, Casimiro S and Costa
L: Bone remodeling markers and bone metastases: From cancer
research to clinical implications. Bonekey Rep. 4:6682015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aft RL, Naughton M, Trinkaus K and
Weilbaecher K: Effect of (Neo)adjuvant zoledronic acid on
disease-free and overall survival in clinical stage II/III breast
cancer. Br J Cancer. 107:7–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Coleman R, de Boer R, Eidtmann H, Llombart
A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J,
Barrios C, et al: Zoledronic acid (zoledronate) for postmenopausal
women with early breast cancer receiving adjuvant letrozole
(ZO-FAST study): Final 60-month results. Ann Oncol. 24:398–405.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gnant M, Mlineritsch B, Stoeger H,
Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M,
Hubalek M, Pristauz G, et al: Adjuvant endocrine therapy plus
zoledronic acid in premenopausal women with early-stage breast
cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol. 12:631–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Coleman R, Cameron D, Dodwell D, Bell R,
Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, et
al: Adjuvant zoledronic acid in patients with early breast cancer:
final efficacy analysis of the AZURE (BIG 01/04) randomised
open-label phase 3 trial. Lancet Oncol. 15:997–1006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Steinman RA, Brufsky AM and Oesterreich S:
Zoledronic acid effectiveness against breast cancer metastases-a
role for estrogen in the microenvironment? Breast Cancer Res.
14:2132012. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frenkel B, Hong A, Baniwal SK, Coetzee GA,
Ohlsson C, Khalid O and Gabet Y: Regulation of adult bone turnover
by sex steroids. J Cell Physiol. 224:305–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wright LE and Guise TA: The
microenvironment matters: Estrogen deficiency fuels cancer bone
metastases. Clin Cancer Res. 20:2817–2819. 2014. View Article : Google Scholar : PubMed/NCBI
|
